Lunit and Agilent Partner on AI Tools for Cancer Diagnostics
SEOUL, South Korea — September 22, 2025 — Lunit and Agilent Technologies have launched a non-exclusive collaboration to co-develop...
drug development
Advertisement
EU Approves ROMVIMZA™, First Therapy for TGCT Patients in Europe
Brussels, Belgium – September 17, 2025 – In a landmark development for rare disease patients, the European Commission (EC)...
Wheeler Bio and MindImmune Partner on Alzheimer’s Therapy MITI-101
OKLAHOMA CITY, Sept. 17, 2025 – Wheeler Bio, Inc., a U.S.-based contract development and manufacturing organization (CDMO), announced today...
Sanguine Enhances Cancer Research with Expanded Biospecimen Offerings
September 16, 2025 — San Diego, California Sanguine Biosciences has announced the expansion of its oncology biospecimen offerings through...
Kodiak’s KSI-101 Delivers Promising Data in Retinal Disease Study
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
Advertisements
Monte Rosa and Novartis Expand Degrader Alliance in Immunology
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
Atossa Pursues FDA Path for Low-Dose (Z)-Endoxifen in Breast Cancer Prevention
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
IDEAYA Biosciences Enrolls First Patient in Phase 1/2 Combination Trial of IDE397 and Trodelvy® in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...
FDA Clears WIDAPLIK™, Developed with Piramal Pharma Solutions
Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO), has collaborated with George Medicines to develop WIDAPLIK™,...
Zydus Therapeutics Reports Positive Topline Results from EPICS-III Trial of Saroglitazar Magnesium in Primary Biliary Cholangitis
Zydus Therapeutics, Inc., a U.S.-based innovation arm of Zydus Lifesciences Ltd., today announced positive topline data from its pivotal...
Advertisement
